Literature DB >> 2150858

Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia.

D M Mann1, M C Royston, C R Ravindra.   

Abstract

The number of senile plaques (SP) and neurofibrillary tangles (NFT) and the number and nucleolar volume of nerve cells have been estimated in certain cortical and subcortical regions in 22 patients with Down's syndrome (DS) and have been related to the patients' age and to the presence and severity of dementia. Elderly (i.e. over 50 years of age) patients showed increased densities of SP and NFT and significant reductions in number and nucleolar volume of nerve cells, when compared with patients under 50 years of age, though the extent of these changes was, in general, no greater in the non-demented elderly group than that in the demented elderly group. Of the younger, nondemented group, those patients with a limited formation of SP and NFT in their brains showed a similar number and nucleolar volume of nerve cells, as those completely devoid of SP and NFT. It is concluded that in DS, formation of SP and NFT predate any significant atrophy and loss of nerve cells and that it is only after the age of 50 years that gross atrophy and loss of neurones occurs, though the extent of this process seemingly does not predict the onset, nor the progress, of dementia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150858     DOI: 10.1016/0022-510x(90)90152-d

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

Review 2.  The pathobiology of lost human potential: schizophrenia as a neurodevelopmental disorder.

Authors:  J L Waddington
Journal:  Ir J Med Sci       Date:  1991-12       Impact factor: 1.568

Review 3.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

4.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 5.  Mouse-based genetic modeling and analysis of Down syndrome.

Authors:  Zhuo Xing; Yichen Li; Annie Pao; Abigail S Bennett; Benjamin Tycko; William C Mobley; Y Eugene Yu
Journal:  Br Med Bull       Date:  2016-10-27       Impact factor: 4.291

6.  Early age-related progression of AD-like neuropathology in Down's syndrome.

Authors:  Larry D Sparks; Richard J Kryscio; John C Hunsaker
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

Review 7.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

8.  Is heart disease a risk factor for low dementia test battery scores in older persons with Down syndrome? Exploratory, pilot study, and commentary.

Authors:  Maire E Percy; Walter J Lukiw
Journal:  Int J Dev Disabil       Date:  2017-04-09

9.  Abnormalities of cerebral structure in schizophrenia on magnetic resonance imaging: interpretation in relation to the neurodevelopmental hypothesis.

Authors:  E O'Callaghan; P Buckley; O Redmond; J Stack; J T Ennis; C Larkin; J L Waddington
Journal:  J R Soc Med       Date:  1992-04       Impact factor: 18.000

10.  Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.

Authors:  Kin Y Mok; Emma L Jones; Marisa Hanney; Denise Harold; Rebecca Sims; Julie Williams; Clive Ballard; John Hardy
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.